The concept of dendritic cell (DC) maturation generally refers to the changes in morphology and function of DCs. Conventionally, DC maturity is based on three criteria: loss of endocytic ability, gain of high-level capacity to present antigens and induce proliferation of T cells, and mobility of DCs toward high concentrations of CCL19. Impairment of DC maturation has been suggested as the main reason for infectivity or chronicity of several infectious agents. In the case of hepatitis C virus, this has been a matter of controversy for the last two decades. However, insufficient attention has been paid to the method of ex vivo maturation as the possible source of such controversies. We previously reported striking differences between DCs matured with different methods, so we propose the use of a standard quantitative index to determine the level of maturity in DCs as an approach to compare results from different studies. We designed and formulated a mathematically calculated index to numerically define the level of maturity based on experimental data from ex vivo assays. This introduces a standard maturation index (SMI) and weighted maturation index (WMI) based on strictly standardized mean differences between different methods of generating mature DCs. By calculating an SMI and a WMI, numerical values were assigned to the level of maturity achieved by DCs matured with different methods. SMI and WMI could be used as a standard tool to compare diversely generated mature DCs and so better interpret outcomes of ex vivo and in vivo studies with mature DCs.
Introduction
Dendritic cells (DCs) play a central role in the immune system by initiating an immune defence process, connecting innate and adaptive immunity, and directing an antigen-specific immune response. They originate from bone marrow and migrate to all tissues, where they stay at an immature stage. After being exposed to and taking up foreign antigens, they start the process of maturation and migrate toward the local lymph nodes, where they present the antigen to T cells ( 
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DC-based vaccines or immunotherapies; in contrast, they are also viewed as mediators of T-cell tolerance, which can be applied to control of autoimmune diseases. 1, 2 Maturation is the hallmark of DCs and most likely the most important event in the process of immune recognition, as it is critical for the efficiency of DCs at presenting antigens to naive T cells, which is their main function. Although described by changes in morphology and function, the concept of DC maturation is not completely understood; it is a process involving changes in many functional aspects of DCs such as phagocytosis, antigen presentation, chemotaxis and cytokine secretion. The conventional definition of DC maturity is usually based on three important criteria including reduction of endocytic ability, increase in the ability to induce T-cell proliferation, and increase in the directional mobility of DCs toward lymph nodes in response to high concentrations of specific chemokines, CCL19 and CCL21.
Different methods are being used to produce mature DCs (mDCs) for ex vivo assays to uncover the biology of DCs, for in vivo animal studies, and even clinical trials. 3 For this purpose, mDCs have been shown to have greater therapeutic benefits than immature DCs (iDCs); [4] [5] [6] [7] [8] in fact, the maturation protocol and level of maturity can determine the magnitude and type of immune response. 9, 10 In addition, studies on DC maturation are becoming more critical as it is hypothesized that impairment of maturation, T-cell stimulatory capacity, or some of their other functions could be the main reason for infectivity or chronicity of some infectious diseases such as those caused by hepatitis C virus, [11] [12] [13] [14] [15] herpes simplex virus, 16 respiratory syncytial virus, 17 human immunodeficiency virus, 18 cytomegalovirus, 19 measles virus, 20 vaccinia virus, 21 varicella zoster virus, 22 Ebola virus, 23 canarypox virus, 24 Borrelia garinii, 25 Mycobacterium tuberculosis, 26 Coxiella burnettii, 27 Salmonella typhi, 28 anthrax lethal factor protein, 29 and
Mycobacterium ulcerans mycolactone, 8, 30 or even the evasion of tumour cells from immune defence. 31 The impact on these pathogens has resulted in tremendous efforts in ex vivo generation of competent mDCs to study the maturation process or to use them for clinical trials. However, controversial results have been reported on the same subject and experimental conditions, a good example being the effects of hepatitis C viral proteins on DC maturation. 15, [32] [33] [34] [35] [36] [37] [38] [39] Several studies strongly support evasion of the virus through significant impairment of DC maturation due to hepatitis C viral proteins, but other reports showed no effect on maturation of DCs in the same context.
We believe that insufficient attention to the maturation method could be the reason for the differences in level of maturity, and the type of mDCs generated in these studies, which in turn may define the type and strength of an immune response. In fact, mDCs reported in different studies could be different entities as we reported elsewhere, 40 although they are presently used under the same name of mDCs for ex vivo assays or in vivo trials. This emphasizes the need for a quantitative definition of maturity and ideally a maturity index for mDCs to be used as a reference to compare the maturity level of mDCs generated with different methods.
The major criteria defining the maturation of DCs are measurable and often measured ex vivo, where mDCs are generated to be used in different studies. Hence, using these parameters to define a standard maturation index to have a clear quantitative description of "Mature Dendritic Cell" would be very useful. This index could help to compare results from different laboratories as well as in the overall use of DCs for different purposes. In addition, by applying a consistent maturity index, the ex vivo experimental simulation of DC maturation could be a guide to gain a better understanding of and approach to the concept of the maturation process in vivo. This then might lead to a more effective procedure for ex vivo generation of mDCs for in vivo use, and even to prediction of the efficacy of those mDCs. Several methods have been proposed in the literature to measure and analyse a statistical effect size, such as mean difference, fold-change, per cent inhibition, per cent activity, per cent viability, Z-score and their robust versions, which have been extensively used for statistical analysis of biological experiments, especially highthroughput screening assays. [41] [42] [43] [44] [45] [46] [47] However, these methods have issues in capturing data variability due to limited sample size, which is a common problem in medical and clinical science. 48 In medical sciences, statistical significance or P-value of a t-test to calculate mean difference has been widely used for comparison of two groups with small sample size; however, it has been intensively criticized, as this method cannot effectively measure the magnitude of the impact due to testing only mean difference. To address this contention, strictly standardized mean difference (SSMD) has been proposed for the comparison of two groups with applications in data analysis in highthroughput screening experiments. 49, 50 It is also being claimed that SSMD measures the magnitude of impact more effectively than any other currently used metrics. 49 Using this method, Zhang has recently explored the relationships between SSMD, standardized mean difference and P-value of classical t-test for comparing two groups. 51 The relationships among these measures suggest that SSMD may serve as an alternative to statistical significance in medical sciences and as an alternative to traditional effect sizes in social sciences. Moreover, SSMD was shown to be an ideal significance test when the sample size is very large (n > 20, as in the case of most medical screening tests), as the precision of the SSMD estimate is increasing with the larger sample sizes, in contrast to the P-value of the t-test, which is decreasing to zero. 51 Here, we hypothesized that SSMD may have the ability to effectively measure the magnitude of maturation impact, and additionally categorize this into a spectrum from extremely weak to extremely strong maturation. Accordingly, we designed and formulated a mathematical equation to measure the level of maturity in mDCs based on experimental data from ex vivo assays, which are measuring six maturation parameters including the surface expression of CD83, CD86 and HLA-DR along with phagocytic, antigen-presenting and chemotactic characteristics of mDCs (functional abilities).
Materials and methods

Biological methods
Generation of monocyte-derived immature and mature dendritic cells. Fast iDCs were generated as described previously. 52 Blood samples were collected from healthy Functional assays. Three key functional aspects of DCs were analysed and compared between different treatments as described previously. 36, 40, 52 Briefly, DCs were evaluated for their ability to take up FITC-conjugated dextran (FITC-DX, Sigma-Aldrich) reconstituted in PBS by using flow cytometry as an indicator of their phagocytic ability. The antigen presentation capabilities of DCs were evaluated with an allo-stimulatory mixed lymphocyte reaction (MLR). Mature DCs were collected, washed in PBS, and analysed for their capacity to induce proliferation of CD4 + T cells from an HLA-mismatched healthy donor using a CellTrace TM CFSE Cell Proliferation Kit (Molecular Probes, Invitrogen, Carlsbad, CA). Chemotaxis assays were performed based on measuring the ability of the DCs to migrate toward a high concentration of CCL19 in the bottom chamber of a 24-well Transwell system (Corning Inc., Corning, NY). Briefly, diluted CCL19 was added to the bottom well of a low-attachment 24-well plate; Trans-well inserts were placed on each well, and 150 ll of cell suspensions was added to the inserts. The plate was incubated at 37°for 2 hr and the cells that migrated to the bottom compartment were harvested and counted by flow cytometry for 1 min.
Mathematical tools
Measuring maturation significance using SSMD. The SSMD is a measure of effect size and is mathematically calculated by dividing the mean by the standard deviation of a difference between two random values; each from one of two groups. SSMD is a statistical parameter measuring effect sizes for the comparison of any two groups with random values. To formulate this, let random variables P 1 and P 2 denote two populations of interest and D denote the difference between P 1 and P 2 . It is assumed that both populations have normal distribution and that P 1 has mean l 1 and variance r .
In order to calculate SSMD, the minimum number of samples should be two to normalize/standardize different parameters' scales and ranges, although in ideal cases it is 10 or more. In our study, the chemotaxis assay was performed in 15 separate experiments with different maturation methods, the MLR was performed in 10 experiments, and CD83 in 12 to 27 experiments depending on the maturation techniques. Our data sheet for each of the parameters (CD83, CD86, HLA-DR, phagocytosis, MLR and chemotaxis) had values for all three methods of maturation (TNF-a, LPS or MC) along with values for iDCs (Nil). For each entry of the chemotaxis parameter as an example, the number of migrated cells was reported, which might range from 27 to 31 188 cells and in each study, any sample of each group had three technical replicates and the result of each replicate was almost the same number with insignificant differences among the three replicates. Therefore, the individual sample size of these experiments is very large and the measured numbers have very small variances. The SSMD and its robust version that is used in the study are indeed proposed for such tests to compare two groups in highthroughput screening experiments (more explanation in refs [49] [50] [51] . These measurements can therefore be performed on different numbers of experiments depending on the parameter. The statistical significance or P value of a t-test strongly depends on the experiment size, and as N?∞, the t-statistic value goes to AE∞ and the P value goes to 0, 51 so the robustness of the SSMD is correlated to the size of the sample and its precision only increases with the number of experiments. Therefore, a single study is enough for calculation of SSMD and the standard maturation index (SMI) index can be calculated even when only one experiment (study) is performed provided that values for both mDCs and iDCs (Nil) exist.
However, when multiple experiments are performed, the SSMD estimate will be even more precise.
Calculating a robust SSMD. As the above-calculated SSMD is not robust enough, mainly due to its vulnerability to outliers, it may be better to calculate the robust version of SSMD (R-SSMD), by using median instead of mean, and median absolute deviation instead of standard deviation. For normally distributed data, to obtain an estimate of standard deviation (r ), mean or median absolute deviation (MAD) is multiplied by a standard constant (K), which is 1Á253 or 1Á4826, depending on whether mean or median is used, respectively. 53, 54 MAD is a consistent estimator of the standard deviation:
In addition, we may remove the outliers from the data set. An outlier is a value that is more than 1Á5 times the interquartile range away from the lower or upper quartile. By applying these changes, a robust version of the SSMD calculation will be obtained.
Definition of SMI based on SSMD. To define and calculate the SMI, we first generated mDCs using three commonly used and well-known methods of maturation, namely TNF-a, LPS and an MC containing IL-1b, IL-6, TNF-a and prostaglandin E 2 , as reported previously, 40 and measured the surface expression of CD83, CD86, HLA-DR, along with phagocytic ability, antigen presentation and chemotaxis of mDCs. These values were used for definition and calculation of SMI as follows:
Chemotaxis ) are the SSMD significant factors measured by CD83, CD86, HLA-DR, phagocytosis, MLR and chemotaxis, respectively. For each vector of this space, there is a vector, which is a uniformly minimal variance unbiased estimate (UMVUE) of b 1 . The SMI is defined as the normalized length of this vector:
Definition of weighted maturation index. It is also possible to give certain measurements more weight to calculate a weighted maturation index (WMI). Let W = (w 1 , w 2 , w 3 , w 4 , w 5 , w 6 ) be a vector of weights, where w i is a positive real number; and let The SMI is a special case of WMI, in which W is the vector w = (1, 1, 1, 1, 1, 1) .
All the functions to calculate SMI and WMI have been coded in Matrix Laboratory Matlabâ scientific scripting language, version R2014b (http://www.mathworks.com).
Results
Mature dendritic cells generated by various treatments display different levels of maturity based on a significant difference in their level of marker expression and functionality
To compare various maturation methods, monocytederived DCs were matured with TNF-a, LPS or MC, and their phenotype was evaluated based on the expression levels of known maturation markers (CD83, CD86 and HLA-DR). DCs matured by MC (MC-mDCs) were the most mature among all treated mDCs (Fig. 2a-f) . The characteristic functional marker for maturation, Cluster of differentiation 83 (CD83), was expressed on~80% of the MC-mDCs, but only on~40% of the LPS-mDCs and 18% of the TNF-a-mDCs (Fig. 2a) . Similarly, expression of CD86, a co-stimulatory molecule that plays a role in antigen presentation, was higher on MC-mDCs than on TNF-a-mDCs or LPS-mDCs (Fig. 2b) . Since the amount of HLA-DR per cell increases during maturation due to translocation from the cytoplasm to the cell surface, the geometric mean fluorescent intensity (MFI) was compared for HLA-DR (Fig. 2c) . This showed that the MFI of HLA-DR was significantly higher in MC-mDCs than in TNF-a-mDCs and LPS-mDCs. These results suggest that MC-mDCs are more mature than TNF-a-mDCs or LPSmDCs based on the expression of maturation markers.
To check the functional characteristics of the mDCs generated by the different treatments, they were checked in an ex vivo phagocytosis assay. As shown in Fig. 2(d) , the phagocytic ability of TNF-a-mDCs and LPS-mDCs was similar, but significantly lower than that of iDCs; the MCmDCs showed an even more significant reduction in their endocytic ability in comparison to iDCs. Furthermore, TNF-a-mDCs, LPS-mDCs and MC-mDCs were evaluated in an allo-stimulatory MLR assay, with CD4 + T cells from an HLA-II mismatched volunteer as responder cells. MCmDCs induced enhanced T-cell proliferation in comparison to all other DCs, which is compatible with improved antigen presentation. However, there was no significant difference between the T-cell proliferation induced by TNF-a-mDCs and LPS-mDCs, suggesting that TNF-amDCs and LPS-mDCs are equally effective at antigen presentation (Fig. 2e) . Finally, a highly significant increase was observed in the level of motility in MC-mDCs in comparison to TNF-a-mDCs and LPS-mDCs in a chemotaxis assay using chemokine CCL19, a ligand for CCR7 (a maturationspecific chemokine receptor on mDCs) (Fig. 2f) . As MC induced the most robust changes in key functions of DCs that rely on maturity, MC-mDCs may be considered more mature than TNF-a-mDCs and LPS-mDCs.
Standardized maturation index is able to effectively and quantitatively define the level of DC maturity First, to visually illustrate the maturation of the DCs with different methods, the effect of the maturation process on CD83, CD86, HLA-DR, phagocytosis, MLR and chemotaxis is shown in Fig. 3(a-f) . The figures show the boxplot of all parameters measured with different methods. This clearly shows that the MC method has a much more significant effect on the outcomes for all parameter sets, whereas LPS was more prominent than TNF-a with the exception of phagocytosis, in which both had very similar effects. These results indicate that CD83, CD86, HLA-DR, phagocytosis and chemotaxis are all good indicators of maturation level, whereas Fig. 3(e) shows that there was little change in MLR, which was only observed in the MC-treated mDCs, indicating that MLR alone may not be a good parameter to compare different maturation methods.
Calculation of SSMD (no robustness)
Strictly standardized mean difference as defined is a population parameter, which needs to be estimated from observed samples. Suppose we have one sample (with sample size n 1 , sample mean X 1 and sample standard deviation S 1 ) from Population P1 and another independent sample (with n 2 , X 2 and S 2 ) from Population P2. Let N = n 1 + n 2 . Zhang derived maximum-likelihood estimate (MLE) and method-of-moment (MM) estimate of unpaired SSMD when the two compared groups have normal distributions with unequal variances. 49 When the two compared groups have normal distributions with equal variance, the UMVUE of unpaired SSMD 50 is,
% N À 3 Á 5 when n 1 !2; n 2 ! 2: 
In the case of unpaired maturation results, it is therefore possible to calculate the SSMD between the iDC and mDC results for each of CD83, CD86, HLA-DR, phagocytosis, MLR and chemotaxis, even for n 1 or n 2 = 1. The SSMD, denoted as b in the equations, is calculated by comparing Nil set and TNF-a, LPS and MC sets of measurements for each parameter (CD83, CD86, HLA-CR, phagocytosis, MLR and chemotaxis). Table 1 shows the results of the analysis. It is worth mentioning that the SSMD calculation is used here with no robustness, and the sets include the possible outliers.
A very interesting characteristic of SSMD shown in Table 1 is that it is a normalized parameter, so the dimensions or magnitudes of different measurements do not TNF-mDCs, mDCs generated with tumour necrosis factor-a (TNF-a); LPS-mDCs, mDCs generated with lipopolysaccharide (LPS); MC-mDCs, mDCs generated with maturation cocktail (MC), containing interleukin1b, interleukin-6, TNF-a and prostaglandin E 2 ; DX-FITC, dextran conjugated with FITC; MLR, mixed lymphocyte reaction. *P < 0Á05, **P < 0Á01, ***P < 0Á001 and ****P < 0Á0001. Note that the P value in (a) for CD83 is < 0Á0001 between each pair of groups. matter, and can be totally different, as in the case for CD83, HLA-DR, phagocytosis and chemotaxis measurements. Another characteristic is that SSMD is positive if the maturation increases the measured data, and is negative if it decreases the measured data, as in the case of phagocytosis.
Improving the method of SSMD calculation by applying robustness
In the calculation of SSMD the assumption is that data have normal distribution. However, when we examined this assumption for CD83 and chemotaxis data sets, the slight deviation from the normal distribution ( Fig. 4a-h ) and the presence of outliers (Fig. 3a-f ) necessitated the use of R-SSMD to overcome the vulnerability to outliers and non-robustness, as described before. 55 Hence, we removed the outliers from data sets and used median instead of mean and MAD instead of standard deviation to calculate R-SSMD as follows:
where X 1 , X 2 , s 1 , and s 2 are the medians and median absolute deviations of the two sets. As shown in Table 2 , the TNF-a and LPS effects were further reduced, while for the MC method the effect was sometimes increased.
According to Table 2 , the calculated R-SSMD strongly differentiates between the methods, being highest for the MC method, whereas it was low for the TNF-a method and moderate for the LPS method. In addition, LPSmDCs had a larger R-SSMD than TNF-a-mDCs, except for phagocytosis and chemotaxis, in which they were very close. These conclusions are the same as the conclusions found by studying the data representations, which suggests that R-SSMD is a suitable technique to implement a standard index for the DC maturation significance. Therefore, for each of these methods the SMI that is based on SSMD would be:
and when we used R-SSMD numbers: 0·0  0·1  0·2  0·3  0·4  0·5  0·6  0·7  Probability   0·0  0·1  0·2  0·3  0·4  0·5  0·6 The calculated robust SMI (R-SMI) for each method was as follows:
To translate this to descriptive expressions, we generated Table 3 and descriptively ranked the level of maturity based on the numbers for R-SMI.
According to Table 3 , where SMI is calculated based on SSMD (Table 1) , the TNF-a maturation method is fairly moderate (rank 5 of 10), the LPS maturation method is strong (rank 8 of 10), and the MC maturation method is very strong (rank 9 of 10). This ranking is not affected for MC-mDCs using R-SSMD (Table 2) , but was changed to fairly weak (rank 4) for TNF-a-mDCs and to moderate (rank 6) for LPS-mDCs. Of course, the thresholds for this categorization may be revised based on a consensus agreement among the experts in the art, such as immunologists. The robustness method did not decrease the rank for MCmDCs, but it reduced the effects of TNF-a and LPS.
Based on this analysis, the MC method is strongly suggested for maturation of iDCs. Furthermore, LPS had a more prominent effect on four of the parameters, and slightly less effect on the other parameters than the TNFa method, and is therefore suggested over TNF-a. This conclusion is very much in agreement and compatible with the intuitive analysis based on Figs 2 and 3.
Calculation of WMI
In order to calculate WMI, it is also possible to give certain measurements more weight. As described in the Materials and methods, SMI is a special case of WMI, in which a weight of 1 is assigned to all six features of maturation. However, in the viewpoint of an immunologist, the motility and capability of mDCs at presenting antigens may be considered as much more important features for mDCs. Hence, as an example, different weight was allocated to the experimentally measured parameters; as such, weight 0Á8 was given to CD83 (as a functional receptor that is involved in antigen presentation), 0Á2 to CD86 and HLA-DR (as accessory molecules in antigen presentation), 0Á5 for phagocytosis as a characteristic function for iDCs (with minimum importance if reduced or not in mDCs), and finally 1 for MLR and chemotaxis as two key functions of mDCs. According to the formulation described in the Materials and methods when w 1 = (0Á8 CD83 , 0Á2 CD86 , 0Á2 HLA-DR , 0Á5 phagocytosis , 1 MLR , 1 Chemotaxis ).
WMI and R-WMI of TNF-mDCs, LPS-mDCs and MCmDCs will be calculated as follows:
In this example set of w 1 , the calculated R-WMIs are slightly different from R-SMIs; however, they did not change the category of maturity for different methods. However, using a different set of values for weight may significantly change the WMI and R-WMI indexes. For example, if we change the weights of only two parameters (CD83 from 0Á8 to 0Á2 and phagocytosis from 0Á5 to 1), the WMI and R-WMI for each of the three methods of maturation would be as follows: 
As shown in Table 4 , by applying the new weights to only two parameters, the WMI and R-WMI indexes decreased in all maturation methods. However, the reduction of the WMI index in the case of LPS-mDCs was more significant than others as it has changed the category of LPS-mDCs from 8 (strong) to 5 (fairly moderate), whereas the TNF-a-mDCs and MC-mDCs categories did not change. In the case of R-WMI, the index moved down from category 6 (moderate) to 5 (fairly moderate) for LPS-mDCs and from category 9 (very strong) to 8 (strong) for MC-mDCs, respectively. This example shows that there is a significant difference between methods of maturation with respect to the features of mDCs. It also indicates the importance of choosing an optimal weight value for each of the mDC characteristics for calculation of WMI and R-WMI. According to our categorization in Table 3 , MC-mDCs seem to be more resistant to changing category, since a wide relaxed range has been allocated to the top part of the spectrum in Table 3 .
Hence, the descriptive classifications and application of weight to this index is important in view of different immunologists' opinions of the importance of maturation features. Recommendations by expert immunologists may result in broadly approved weight values for each of the maturity features and a more comprehensive table for descriptive classifications of mDCs. In addition, future studies may uncover and suggest the inclusion of new parameters or even exclusion of some of the current ones. Briefly, the weights can be best defined according to a consensus agreement among the experts in the art, including biologists and cellular immunologists.
Discussion
In this study, we for the first time designed and formulated mathematically based maturity indexes (SMI and WMI) based on the data obtained for three different and common methods of DC maturation in one laboratory. Recently, SSMD has been proved to be the best measure for effect size in biological and sociological studies. The study provides a method to approximate the maturity of DCs, and combines different parameters with different scales and ranges into a standardized index. The method needed to be standardized as raw measurements expressed with different units, scales and ranges cannot be combined together to define an index. For instance, for CD83, the percentage of cells expressing CD83 is reported and is between 1%-100%, whereas for chemotaxis the absolute number of migrating cells ranges from 27 to 31 188, and for HLA-DR the intensity of the expression of the marker ranges from 33 to 322 in our experiments. Even within the same scale and unit, the ranges of the changes are different. If the method were not standardized, heterogeneous units with different scales would have created errors in calculation by misleadingly reducing the effects of a factor such as CD83 where its maximum raw value reaches 100 in a fully matured DC in comparison to chemotaxis where its minimum value for an immature DC could be 100. The method also provides room for further additions of other parameters in the future, and there would be no issue with the range of these potential new additions in this standardized scheme, as every scale and unit can be standardized to a value between 0 and 1 before being added to the index. Here, we have shown that a robust implementation of SSMD (R-SSMD) can effectively determine the level of maturation and robustly discriminate strongly matured and moderately matured DCs from each other through defining SMI, which can be further extended as WMI. This allows us to show the significance and biological relevance of different maturation criteria according to commonly accepted features of mDCs by biologists and immunologists. Although different aspects of mDCs have been explained, a full comprehensive list of characteristics for mDCs and iDCs is yet to be discovered. The most agreed feature of DC maturation is that a DC is changing from being a phagocytic cell to becoming a strong antigen-presenting cell. This should be accompanied by high motility capacity, as DCs have to migrate to the lymph nodes to present the captured antigens. Some of the cell surface markers are shown to be changing during this process, too. Here, we have explained and used six common features that discriminate mDCs from iDCs to define a maturity index, three cell surface markers (CD83, CD86 and HLA-DR) and three functions (phagocytosis, antigen presentation and chemotaxis). As these features are different in their specificity and importance in defining mDCs, we propose to use different weights assigned to each of them to be added as a factor to the SMI calculation extending it to WMI. Therefore, the highest score of 1 was allocated to antigen presentation as the main role defined for mDCs. The same weight score of 1 was proposed for chemotaxis because mDCs need to migrate to the lymph nodes to properly accomplish their antigen presentation function. A lower score of 0Á2 was considered for cell surface markers CD86 and HLA-DR, due to lack of specificity to mDCs and the simplicity of being a surface marker rather than a function. However, a high score of 0Á8 was given to CD83 because it is shown to be playing a significant role in antigen presentation; it is also very specific to mDCs. [56] [57] [58] Phagocytosis received a score of 0Á5 as it is a function that is no longer required by DCs at the mature stage. However, as lack of phagocytic ability is still indicative of progress toward mDCs and change in a function is a more complicated process in comparison to change in a marker, it has received a higher score in comparison to CD86 and HLA-DR. In addition, we were cautious with this property as some of the mDCs may still keep their phagocytic capability after maturation. Briefly, in our formulation of WMI, we have given more weight to antigen presentation and chemotaxis as two main critical functional features and to CD83 as the main functional marker in antigen presentation of a competent mDC. Our analyses demonstrated that the SMI is fully capable of describing the magnitude and level of maturity in ex vivogenerated mDCs, which could be further modified based on any desired features of maturation by giving more weight to any specific parameter(s) of interest in WMI. According to the biological definition of the level of maturity for mDCs generated with these three different methods, the SMI and WMI were shown to be appropriate to define the level of maturity, and hence, could be used as a standard tool to compare diversely generated mDCs from different laboratories. This formula combines six key characteristics of mDCs to calculate the relative maturity of mDCs, which is instrumental in comparing the functional potential of mDCs generated in different laboratories with different methods.
As confirmed by flow cytometry and functional assays, the calculated SMI/WMI is highly compatible with the state of maturation from the viewpoint of a biologist/immunologist. By including more variables in the formula by the experts in the field, SMI/WMI could become a key and reliable index to evaluate the process and method of DC maturation in different studies on the same subject. It is also helpful in predicting the potential of ex vivo-generated mDCs to induce the desired immune response when they are used for therapeutic purposes in DC-based vaccines or immunotherapies, especially in cancer therapy trials.
In addition, engagement of SMI/WMI can be applied in the exciting field of tolerance induction or crosspresentation of exogenous, endogenous or apoptotic peptides to CD8 T cells, which are other interesting research subjects to focus on. In this context, we propose to assess an ex vivo system, with various methods of DC maturation, with the purpose of studying the impact of different levels of DC maturity on mediating switching between T helper type 1 and T helper type 2 immune responses. We could then develop a formula that measures a specific response ex vivo using the computational methods of SMI/WMI. The antigen can be different strains of influenza virus or other model viruses like respiratory syncytial virus or hepatitis C virus. For validation, we would eventually be able to test ex vivo experimental results and the SMI/WMI predictions in vivo using a mouse model.
The proposed method can be used for very small sample numbers, namely just two iDC and one mDC samples as an extremely low example. The method can also be used for paired or unpaired samples. Although the details for the paired samples have not been shown, they are essentially based on the same process, the paired SSMD estimations. 49 Using this approach, the standard paired and weighted paired maturity indices can be easily calculated for any paired data set. Finally, it is worth mentioning that there are many aspects of this method that can be studied further, most importantly, revised standard maturity thresholds for maturity application.
The use of a standard index that explains the level of maturity of mDCs could be an efficient tool to compare mDCs generated using different methods by different laboratories. This may explain controversial reports on one and the same subject in the literature, where mDCs are used for ex vivo or in vivo studies.
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